Literature DB >> 31230197

Indications and efficiency of dapsone in IgA vasculitis (Henoch-Schonlein purpura): case series and a review of the literature.

Céline Roman1, Bogdan Dima1,2, Laurence Muyshont1, Thierry Schurmans1, Olivier Gilliaux3.   

Abstract

Immunoglobulin A (IgA) vasculitis (Henoch-Schonlein purpura (HSP)) is the most common vasculitis in children. It is characterized by purpuric rash, arthritis, gastrointestinal, and/or renal involvement. Spontaneous resolution is the typical outcome. In chronic cutaneous manifestations of IgA vasculitis, dapsone seems to show a good effectiveness. Multiple case reports and case series about dapsone in chronic IgA vasculitis are available. However, no clear evaluation of its indications, its effectiveness, or its usage guidelines (optimal dosage or duration of treatment) is available. We reviewed the published cases of IgA vasculitis treated by dapsone and compared them with 2 similar cases that we encountered. Seventeen patients (ranging from 22 months old to 16 years old) with severe or persistent clinical signs of IgA vasculitis were included. Dapsone showed good results on the resolution of cutaneous lesions but not on renal manifestations. Complications (methemoglobinemia) were observed on 1 patient. Half of the patients relapsed after treatment discontinuation. The difference between the time lapse before initiation and the duration of the treatment was not significant.
Conclusion: We suggest that dapsone can have a positive effect in chronic IgA vasculitis when cutaneous manifestations last more than 6 weeks at the dosage of 1-2 mg/kg once per day during 1 week. What is Known: • IgA vasculitis or Henoch-Schonlein purpura is the most common vasculitis in children and affects mostly small vessels of the skin, kidney, and gastrointestinal tract. It resolves spontaneously in most of the cases. Exceptionally, cutaneous lesions can last several weeks. • Dapsone is a bacteriostatic antibacterial sulfonamide drug found to be effective in the treatment of some inflammatory dermatological diseases like IgA vasculitis. What is New: • Dapsone is effective against chronic purpuric lesion (> 6 weeks) at the minimal dose of 1 mg/kg/day. • Relapse occurs frequently after discontinuation but responds after a second course of treatment. A longer duration of treatment or a delay in treatment by dapsone does not seem to influence the relapse rate.

Entities:  

Keywords:  Child; Dapsone; Henoch - Schonlein purpura; IgA vasculitis

Mesh:

Substances:

Year:  2019        PMID: 31230197     DOI: 10.1007/s00431-019-03409-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  22 in total

1.  Dapsone therapy for Henoch-Schönlein purpura: a case series.

Authors:  H Iqbal; A Evans
Journal:  Arch Dis Child       Date:  2005-09       Impact factor: 3.791

2.  Dapsone therapy for Henoch-Schonlein purpura.

Authors:  J I Shin; J S Lee; K S Chung
Journal:  Arch Dis Child       Date:  2006-08       Impact factor: 3.791

3.  Clinical update: Henoch-Schönlein purpura.

Authors:  Frank T Saulsbury
Journal:  Lancet       Date:  2007-03-24       Impact factor: 79.321

4.  EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides.

Authors:  S Ozen; N Ruperto; M J Dillon; A Bagga; K Barron; J C Davin; T Kawasaki; C Lindsley; R E Petty; A M Prieur; A Ravelli; P Woo
Journal:  Ann Rheum Dis       Date:  2005-12-01       Impact factor: 19.103

5.  Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature.

Authors:  Sandra Trapani; Annalisa Micheli; Francesca Grisolia; Massimo Resti; Elena Chiappini; Fernanda Falcini; Maurizio De Martino
Journal:  Semin Arthritis Rheum       Date:  2005-12       Impact factor: 5.532

6.  Immunoglobulin-A--associated small-vessel vasculitis: a 10-year experience at the Massachusetts General Hospital.

Authors:  Katy R Linskey; Daniela Kroshinsky; Martin C Mihm; Mai P Hoang
Journal:  J Am Acad Dermatol       Date:  2011-07-27       Impact factor: 11.527

Review 7.  Dapsone and sulfones in dermatology: overview and update.

Authors:  Y I Zhu; M J Stiller
Journal:  J Am Acad Dermatol       Date:  2001-09       Impact factor: 11.527

8.  EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria.

Authors:  Seza Ozen; Angela Pistorio; Silvia M Iusan; Aysin Bakkaloglu; Troels Herlin; Riva Brik; Antonella Buoncompagni; Calin Lazar; Ilmay Bilge; Yosef Uziel; Donato Rigante; Luca Cantarini; Maria Odete Hilario; Clovis A Silva; Mauricio Alegria; Ximena Norambuena; Alexandre Belot; Yackov Berkun; Amparo Ibanez Estrella; Alma Nunzia Olivieri; Maria Giannina Alpigiani; Ingrida Rumba; Flavio Sztajnbok; Lana Tambic-Bukovac; Luciana Breda; Sulaiman Al-Mayouf; Dimitrina Mihaylova; Vyacheslav Chasnyk; Claudia Sengler; Maria Klein-Gitelman; Djamal Djeddi; Laura Nuno; Chris Pruunsild; Jurgen Brunner; Anuela Kondi; Karaman Pagava; Silvia Pederzoli; Alberto Martini; Nicolino Ruperto
Journal:  Ann Rheum Dis       Date:  2010-05       Impact factor: 19.103

Review 9.  Effects of corticosteroid on Henoch-Schönlein purpura: a systematic review.

Authors:  Pamela F Weiss; James A Feinstein; Xianqun Luan; Jon M Burnham; Chris Feudtner
Journal:  Pediatrics       Date:  2007-11       Impact factor: 7.124

10.  A randomized, placebo-controlled trial of prednisone in early Henoch Schönlein Purpura [ISRCTN85109383].

Authors:  Adam M Huber; Jim King; Peter McLaine; Terry Klassen; Mary Pothos
Journal:  BMC Med       Date:  2004-04-02       Impact factor: 8.775

View more
  6 in total

1.  Dapsone in immunoglobulin A-associated vasculitis.

Authors:  Vera Ramelli; Pietro O Rinoldi; Mario G Bianchetti; Sebastiano A G Lava; Gian Paolo Ramelli; Gregorio P Milani
Journal:  Eur J Pediatr       Date:  2019-10-19       Impact factor: 3.183

2.  Dioscin alleviates lipopolysaccharide-induced acute lung injury through suppression of TLR4 signaling pathways.

Authors:  Chuntao Wang; Qingnian Li; Tianyu Li
Journal:  Exp Lung Res       Date:  2020-01-14       Impact factor: 2.459

3.  Low-dose corticosteroid with mizoribine might be an effective therapy for elderly-onset ISKDC grade VI IgA vasculitis.

Authors:  Hikaru Sugimoto; Shiho Matsuno; Noriko Yamanaka; Wako Yumura; Mitsuyo Itabashi; Takashi Takei
Journal:  CEN Case Rep       Date:  2020-08-04

Review 4.  IgA Vasculitis in Adults: a Rare yet Challenging Disease.

Authors:  Kinanah Yaseen; Leal C Herlitz; Alexandra Villa-Forte
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

5.  Risk factors of renal trauma in children with severe Henoch-Schonlein purpura and effect of mycophenolate mofetil on pediatric renal function.

Authors:  Minhui Li; Binbin Guo; Xue Wang; Yingying Zhang
Journal:  Transl Pediatr       Date:  2021-12

Review 6.  IgA vasculitis.

Authors:  Evangéline Pillebout; Cord Sunderkötter
Journal:  Semin Immunopathol       Date:  2021-06-25       Impact factor: 9.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.